迈入千亿市值俱乐部的后续。《投资者网》蔡俊近期，信达生物（01801.HK，下称“公司”）拿下百亿交易。根据公告，公司将通过对外合作的方式，有望进军北美市场。一方面，公司需在三年时间完成200亿元产品销售目标，既往的研发管线和销售组织都以此展开。另一方面，公司迈入千亿市值俱乐部后，锚定更宏大的目标或是下一步目标。资本看穿交易的“底牌”10月，公司公告与武田制药达成合作，向后者授予IBI363、...
Source Link迈入千亿市值俱乐部的后续。《投资者网》蔡俊近期，信达生物（01801.HK，下称“公司”）拿下百亿交易。根据公告，公司将通过对外合作的方式，有望进军北美市场。一方面，公司需在三年时间完成200亿元产品销售目标，既往的研发管线和销售组织都以此展开。另一方面，公司迈入千亿市值俱乐部后，锚定更宏大的目标或是下一步目标。资本看穿交易的“底牌”10月，公司公告与武田制药达成合作，向后者授予IBI363、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.